Granite Point Capital Management, L.P. Dbv Technologies S.A. Transaction History

Granite Point Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 13, 2018	SELL	$18.6 - $24.94 $491,040 - $658,416	-26,400 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$20.86 - $26.6 $283,696 - $361,760	-13,600 Reduced 34.0%	26,400 $609,000
Q3 2017 Nov 14, 2017	BUY	$39.62 - $46.17 $1.58 Million - $1.85 Million	40,000	40,000 $1.7 Million

37.7M

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $158M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.